Avalyn Pharma Cash Flow Statement
NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalyn Pharma has no annual cash flow statement on file yet, so quarterly figures are shown instead.
Avalyn Pharma free cash flow
In the quarter ended Jun 30, 2026, Avalyn Pharma generated -$26.1 million of operating cash flow and spent $269,000 on capital expenditures. That left free cash flow of -$26.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Avalyn Pharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -28.93M | -26.87M | -20.19M | -17.50M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 110.00K | 63.00K | 9.00K | 10.00K |
| Stock-Based Compensation | 2.79M | 1.19M | 1.13M | 543.00K |
| Change in Working Capital | -184.00K | -3.58M | -893.00K | -1.50M |
| Operating Cash Flow | -26.08M | -29.89M | -20.70M | -19.27M |
| Capital Expenditures | -269.00K | -318.00K | 0 | -8.00K |
| Investing Cash Flow | -118.71M | 55.02M | -36.69M | 24.12M |
| Financing Cash Flow | 316.67M | 14.86M | 89.88M | 0 |
| Free Cash Flow | -26.34M | -30.21M | -20.70M | -19.28M |
This table shows 4 quarterly periods of Avalyn Pharma's cash flow statement, from Q2 2026 back to Q? 2025, across 9 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AVLN's reporting calendar. What is a cash flow statement?